REG - Argent Biopharma Ltd - Dr. Shlomo Sadoun Joins Advisory Board
15/04/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240415:nRSO4839Ka&default-theme=true
RNS Number : 4839K Argent Biopharma Limited 15 April 2024
15 April 2024
Argent BioPharma Ltd.
Dr. Shlomo Sadoun Joins Argent BioPharma Ltd Advisory Board
Argent BioPharma Ltd (Argent BioPharma or the Company), an innovative drug
discovery company within the biopharmaceutical sector, is pleased to announce
Dr. Shlomo Sadoun has joined Argent BioPharma's advisory board with immediate
effect.
Dr. Shlomo Sadoun has over 18 years of experience in the pharmaceutical
sector. Dr. Sadoun co-founded and leads SK-Pharma Group, a global
pharmaceutical company operating in 18 countries. SK-Pharma specialises in
producing and marketing generic, specialty pharma, hybrid generics, and
biosimilar pharmaceutical products. Additionally, Dr. Sadoun serves as the CEO
of Arphio, an orphan drug company utilising proprietary technology to promote,
market, and sell orphan drugs worldwide.
Dr. Sadoun's expertise lies in leveraging technology to redefine business
processes. He has established strategic alliances with over 200 innovative
companies and launched more than 300 products globally, many of which were
pioneering and branded. Dr. Sadoun's adeptness in utilising technological
advancements has propelled SK-Pharma to become the fastest-growing
pharmaceutical group in Israel and beyond. Dr. Sadoun holds a master's degree
in Global Management from Salford University and a Doctorate in Business
Administration from the Royal Academy of Economics and Technology in
Switzerland, with a focus on public health.
Roby Zomer, Managing Director and CEO of Argent BioPharma, commented: "We are
delighted to welcome Dr. Shlomo Sadoun, an esteemed addition to our advisory
board. With his wealth of experience and expertise in the pharmaceutical
sector, Dr. Sadoun will undoubtedly provide invaluable insights and guidance
as we embark on our new strategic direction. His appointment reaffirms our
commitment to fostering a diverse and knowledgeable advisory board, dedicated
to driving innovation and growth in our Company."
-Ends-
Authorised for release by the board of directors, for further information
please contact:
Argent BioPharma Argent BioPharma
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@argentbiopharma.co.uk (mailto:info@argentbiopharma.co.uk) info@argentbiopharma.co.uk (mailto:info@argentbiopharma.co.uk)
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe / Zach Cohen Aimee McCusker / Adam Pollock
+44 203 934 6630 +44 203 179 5300
argentbiopharma@investor-focus.co.uk aimeemccusker@oberoninvestments.com
(mailto:argentbiopharma@investor-focus.co.uk) (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
(mailto:adampollock@oberoninvestments.com)
About Argent BioPharma
Argent BioPharma is dedicated to meeting unmet medical needs by combining
PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader
in the biopharmaceutical sector. Our mission centres on researching and
developing ground-breaking treatments for worldwide health issues, guided by
strategic principles such as pioneering life science advancements, ensuring
global access, fostering continuous innovation, and striving for industry
leadership.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAGPUPWCUPCGGP